PACS — PACS Group, Inc.

PACS Group Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $1.36 billion, a 12% increase year-over-year.
• Q4 Net Income: $59.8 million.
• Q4 Adjusted EBITDAR: $237.7 million.
• Q4 Adjusted EBITDA: $142.1 million.
• Full Year 2025 Revenue: $5.29 billion, up 29% from 2024.
• Full Year Net Income: $191.5 million; diluted EPS of $1.22.
• Full Year Adjusted EBITDAR: $883.9 million; Adjusted EBITDA: $505 million.
• Average Occupancy: 89.1% for the year; mature facilities at 94.9%.
• Net Leverage: Approximately 0.3x, indicating a strong balance sheet.

2. Strategic Updates and Business Highlights

• PACS executed 8 strategic acquisitions in 2025, enhancing market density and local scale.
• The company operates 321 facilities across 17 states, serving over 31,700 patients daily.
• Focused on integrating and optimizing the expanded portfolio, with positive trends in quality ratings and occupancy.
• 73.4% of skilled nursing facilities rated 4 or 5 stars by CMS, with an average star rating of 4.4.
• Continued investment in leadership development through the Administrator in Training (AIT) program, with 38 participants currently.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $5.65 billion to $5.75 billion, representing an 8% growth over 2025.
• 2026 Adjusted EBITDA Guidance: Expected between $555 million to $575 million, with a midpoint of $565 million, indicating nearly 12% growth.
• The outlook is based on steady organic growth, improved occupancy, and disciplined capital allocation.

4. Challenges and Points of Concern

• Ramping facilities saw a decline in occupancy to 86.3% from over 93% the previous year, reflecting the transition of facilities into ramping status.
• New facilities averaged 81.1% occupancy, down from 82.8% in 2024, indicating ongoing stabilization challenges.
• Pricing for acquisitions has increased due to inflation and rising real estate costs, though there are signs of stabilization in the market.

5. Notable Q&A Insights

• Payer Conversations: The company is well-positioned to negotiate favorable contracts as facilities improve quality metrics, enhancing attractiveness to insurers.
• M&A Pipeline: PACS aims to acquire about 5 facilities per quarter in 2026, with a robust pipeline of potential deals.
• De Novo Activity: While acquisitions remain the primary growth strategy, PACS is open to de novo projects if they align with strategic goals.
• Value-Based Purchasing: The company feels confident about adapting to new reimbursement models tied to quality metrics, viewing it as an opportunity rather than a risk.

Overall, PACS Group demonstrated strong financial performance in 2025, with a focus on strategic growth through acquisitions and operational excellence, while facing challenges related to occupancy in ramping facilities and rising acquisition costs. The outlook for 2026 remains optimistic, supported by a solid balance sheet and ongoing improvements in quality metrics.